Matrix Clinical Research | Los Angeles, CA
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to <24 months.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Note: Other protocol-defined inclusion/exclusion criteria apply.
Primary purpose
Allocation
Interventional model
Masking
310 participants in 10 patient groups, including a placebo group
Loading...
Central trial contact
Moderna Clinical Trials Support Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal